The additional data she presents supports our argument that the deployment of intramuscular MTX is a helpful therapeutic step in the RA treatment algorithm and may avoid the necessity for progression to anti-TNF-treatments. Presumably, in this they are highly cost effective. The safety profile of the treatment in this reported study seems acceptable. The fact that this is a prospective study adds additional weight to the conclusion though, like our study, the numbers of patients are low. We also note a recently published study by Braun et al.
[2] whose conclusions are in line with our own and those of Thornton and colleagues. For our part, we believe that careful consideration should be given to the introduction of subcutaneous MTX in the formulation of guidelines for the treatment of rheumatoid disease. 
